Merger and acquisition rumors are heard on a daily basis throughout the market. Some have merit and turn out to be true, while others turn out to be false and without merit. Today, I will cover some companies that I…
Tag: swing trade
Bullish Free Articles Bullish Premium Articles Commentary Free Articles Commentary Premium Articles Free Articles Premium Articles
Edited: Is An Acquisition Of Solta Medical Imminent?
In my last article concerning Solta Medical Devices (SLTM), I remarked several times how I feel the company has good assets and the potential to grab significant market share in various segments. However, I do feel the company and its…
Scott’s Mid-Week Market Commentary For Week Aug 6 – 9/2013
Scott’s Mid-Week Market Commentary For Week Aug 6 – 9/2013. $ONTX $INSM $AEGR $AUXL plus commentary on Market conditions and current chatter concerning the latest “terrorist threats,” and more!
Biodel Video Chart Analysis
My Biodel Chart Analysis Video – StockMatusow.com ‘s price target opinion for this catalyst run-up trade is around $6
Significant Near Term Catalyst Should Further Rally Keryx Pharmaceuticals
Recently, we have detailed companies that have released positive Phase III data because we believe several of these companies continue to be under speculation value. Companies who have strong management, cash, and a strong pipeline can be very profitable for…
Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Rally Insmed
The Orphan Drug Act was passed in January 1983 to encourage companies to develop drugs that treat rare medical conditions. Companies that receive Orphan Drug Status gain certain financial incentives such as a longer period of exclusivity, enhanced patent protection,…
AVEO Pharma’s Tivozanib Likely To Be Approved
With the current record market run, small cap biopharmas have kept pace and continue to trend higher, being one of the best sectors for both trading and investing over the past year. With 39 new drugs approved, 2012 showed the…
UPDATED: Cyclacel Pharma: Undervalued With Its Potential Blockbuster Drug
Cyclacel Pharmaceuticals (NASDAQ: CYCC) is a development-stage biopharmaceutical company dedicated to the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases. Cyclacel’s strategy is to build a diversified biopharmaceutical business focused in hematology and…
XenoPort Catalyst DD – December 31st
Catalyst: XenoPort conducted an End-of-Phase 2 meeting with the FDA in which it received feedback that a proposed development program for XP21279, a novel prodrug of levodopa, could support a potential New Drug Application (NDA) submission under Section 505(b)(2) of…
